8-K: PROCEPT BioRobotics Reports Strong Q2 2024 Results, Raises Full-Year Guidance

PROCEPT BioRobotics announced a 61% increase in revenue for the second quarter of 2024 and raised its full-year revenue and EBITDA guidance.

Summary

• PROCEPT BioRobotics reported a total revenue of $53.4 million for the second quarter of 2024, marking a 61% increase compared to the same period in 2023.
• U.S. handpiece and consumables revenue saw a significant jump, reaching $27.3 million, a 101% increase year-over-year.
• The company sold 47 robotic systems in the U.S. during the quarter.
• U.S. system and rental revenue totaled $17.8 million, a 20% increase compared to the prior year.
• International revenue also grew substantially, reaching $5.7 million, a 79% increase year-over-year.
• Gross margin improved to 59% in the second quarter of 2024, up from 56% in the prior year period.
• The company's net loss was $25.6 million for the quarter, similar to the $25.3 million loss in the prior year period.
• Adjusted EBITDA loss was $18.0 million, an improvement from the $19.9 million loss in the prior year period.
• Cash and short-term investments totaled $214.1 million as of June 30, 2024.
• The company has increased its full-year 2024 revenue guidance to approximately $217 million and improved its EBITDA guidance to a loss of $67.5 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved gross margins, and increased full-year guidance. While the company is still operating at a loss, the improvements and positive outlook suggest a strong trajectory.

Positives

• The company experienced strong revenue growth across all segments of the business.
• U.S. handpiece and consumables revenue more than doubled year-over-year.
• International revenue showed substantial growth.
• Gross margin improved, indicating better profitability.
• The company improved its full-year revenue and EBITDA guidance.
• Cash usage significantly improved from the first quarter of 2024.
• U.S. monthly utilization per account increased by approximately 15%.

Negatives

• The company reported a net loss of $25.6 million for the quarter.
• Operating expenses increased to $58.3 million, driven by sales and marketing and research and development expenses.
• The company is still operating at a loss, with an adjusted EBITDA loss of $18.0 million for the quarter.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Increased operating expenses could impact future profitability.
• The company is still operating at a loss, which could impact its ability to fund future growth.

Future Outlook

The company has increased its full-year 2024 revenue guidance to approximately $217 million and improved its EBITDA guidance to a loss of $67.5 million. The company projects full year 2024 gross margin to be approximately 59% and total operating expense of approximately $231.5 million.

Management Comments

• We are pleased to report another successful quarter with annual revenue growth of 61%.
• This outstanding performance across all segments of the business reflects continued focus on penetrating BPH hospitals, increasing utilization, and driving operational efficiencies across the organization.
• Additionally, we achieved record gross margins of 59% and demonstrated significant operating expense leverage.

Industry Context

The company's strong performance reflects a growing demand for minimally invasive surgical robotic systems in urology, particularly for the treatment of BPH. This is in line with the broader trend of increasing adoption of robotic surgery due to its potential for improved patient outcomes and reduced recovery times.

Comparison to Industry Standards

• Intuitive Surgical, a leader in robotic surgery, reported a 15% increase in system placements in their most recent quarter, while PROCEPT BioRobotics reported 47 system sales in the US alone, indicating a strong growth trajectory.
• Globally, the surgical robotics market is experiencing rapid growth, with companies like Stryker and Medtronic also investing heavily in this space. PROCEPT's 61% revenue growth is significantly higher than the average growth rate of the overall market, suggesting a strong competitive position.
• The company's gross margin of 59% is competitive with other medical device companies, but there is still room for improvement as the company scales its operations.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and increased guidance.
• Employees may benefit from the company's growth and success.
• Customers (hospitals and surgeons) will have access to advanced surgical technology.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company will host a conference call on August 1, 2024, to discuss the second quarter 2024 financial results.

Key Dates

Keywords

PROCEPT BioRobotics, surgical robotics, urology, AquaBeam Robotic System, BPH, revenue, EBITDA, gross margin, financial results, robotic systems, handpieces, consumables